Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

The launch of GLP-1 weight loss drugs in India is gaining popularity. Harvard researchers share a comprehensive guidance for ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

While Mounjaro offers clinicians a newer option for patients, the medicine alone is not a solution. "The rise in obesity and type 2 diabetes presents a significant public health challenge in India.

Wegovy launch in India challenges Eli Lilly's Mounjaro Analysts say Wegovy priced competitively to Mounjaro Novo faces competition from generic drugmakers Wegovy 0.25 mg, 0.5 mg and 1 mg available ...

For people who constantly think about what they are going to eat meal to meal, their food noise goes down significantly’ ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a majority of the population ...